H.C. Wainwright raised the firm’s price target on Enlivex Therapeutics (ENLV) to $7 from $6 and keeps a Buy rating on the shares after the company announced that the China National Intellectual Property Administration had issued a notice of allowance for patent application 2020800620493. The Chinese patent claims are allowed, covering Allocetra application in treatment of osteoarthritis, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENLV:
- Enlivex Secures Chinese Patent Allowance for Osteoarthritis Treatment
- Enlivex Therapeutics receives notice of allowance for Chinese patent
- Enlivex Reports Promising Interim Results in Osteoarthritis Trial
- Enlivex Reports Promising Interim Results in Knee Osteoarthritis Trial
- Enlivex announces interim 6-month efficacy data from Phase I of Allocetra trial